Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine

Ann Hematol. 2016 Apr;95(5):847-9. doi: 10.1007/s00277-016-2627-9. Epub 2016 Mar 2.

Authors

Li-Mei Poon¹, Yok-Lam Kwong²

Affiliations

¹ Department of Hematology-Oncology, National University Cancer Institute of Singapore, Singapore, Singapore.
² Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China. ylkwong@hkucc.hku.hk.

PMID: 26931114
DOI: 10.1007/s00277-016-2627-9

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adolescent
Allografts
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
Brentuximab Vedotin
Combined Modality Therapy
Drug Resistance, Neoplasm
Epstein-Barr Virus Infections / drug therapy*
Female
Hematopoietic Stem Cell Transplantation
Herpesvirus 4, Human / isolation & purification
Humans
Immunoconjugates / administration & dosage
Immunophenotyping
Ki-1 Antigen / analysis
Ki-1 Antigen / immunology
Lymphoma, Extranodal NK-T-Cell / drug therapy*
Lymphoma, Extranodal NK-T-Cell / therapy
Lymphoma, Extranodal NK-T-Cell / virology
Lymphoma, Primary Cutaneous Anaplastic Large Cell / drug therapy*
Lymphoma, Primary Cutaneous Anaplastic Large Cell / therapy
Lymphoma, Primary Cutaneous Anaplastic Large Cell / virology
RNA, Viral / analysis
Remission Induction
Salvage Therapy*
Skin Neoplasms / drug therapy*
Skin Neoplasms / therapy
Skin Neoplasms / virology
Tumor Virus Infections / drug therapy*

Substances

Epstein-Barr virus encoded RNA 1
Epstein-Barr virus encoded RNA 2
Immunoconjugates
Ki-1 Antigen
RNA, Viral
Brentuximab Vedotin
Bendamustine Hydrochloride